Xvivo Perfusion AB (publ) (XVIVO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Xvivo Q3 report for 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Christopher Rosenblatt and CFO Christopher Nordstrom. Please go ahead. Thank you so much, and good morning and good afternoon, everyone. And especially welcome to Equivo's earning call for the third quarter of 2025. First, a quick introduction of today's presenters. That's me, Christopher Rosenblatt, CEO, calling in from Gothenburg, Sweden. And we also have Christopher Nordstrom, CFO, calling in from Philadelphia in the United States. And with that, we go to the third slide, which shows Q3 financials at a glance. The Q3 shows plus six top line organic growth if adjusted for the U.S. hot trial revenue compared to the same quarter last year. We can note that there was no destocking during Q3, and hence the EBITDA recovered to expected levels during the quarter. In terms of segment growth, the thoracic cells were affected by lower heart study revenue in the U.S. and softer Q3 lung market. The abdominal segment shows great progress for both liver and kidney. Looking a little bit into the future, in the beginning of October, the three out of the four clinics that acquired an XPS in the United States during age one, or up to one, are up and running now in the beginning of October. And we also held a lung master class. I will come back to that later. Yesterday, where it was noted that October at least started better than Q3 in terms of lung transplants and in terms of EVLP support for the lung transplants if you compare to what we saw in Q3. Going into our abdominal segment, live...